ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Drug Discovery

AbbVie and Harvard strike $30 million virus research and drug discovery alliance

by Ryan Cross
September 3, 2020 | APPEARED IN VOLUME 98, ISSUE 34

 

The North Chicago–based drug firm AbbVie has struck a $30 million, 3-year research partnership with Harvard Medical School focused on coronaviruses and emerging pathogens. The collaboration will include immune system research as well as efforts to discover both small-molecule and antibody drugs. AbbVie is testing its Bruton’s tyrosine kinase inhibitor to help reduce cytokine storms in people with COVID-19 and is developing a monoclonal antibody that targets the novel coronavirus.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment